• SPX
  • $5,713.91
  • 0.25 %
  • $13.97
  • DJI
  • $42,094.05
  • 0.2 %
  • $82.46
  • N225
  • $38,635.62
  • 0.22 %
  • $83.56
  • FTSE
  • $8,289.42
  • 0.08 %
  • $6.90
  • IXIC
  • $18,013.03
  • 0.53 %
  • $94.56
C4 Therapeutics, Inc. (CCCC) Stock Price, News & Analysis

C4 Therapeutics, Inc. (CCCC) Stock Price, News & Analysis

Currency in USD Disclaimer

$5.31

-$0.03

(-0.56%)

Day's range
$5.21
Day's range
$5.48
50-day range
$4.56
Day's range
$7.36
  • Country: US
  • ISIN: US12529R1077
52 wk range
$1.06
Day's range
$11.88
  • CEO: Mr. Andrew J. Hirsch M.B.A.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -0.79
  • Piotroski Score 4.00
  • Grade Equal-Weight
  • Symbol (CCCC)
  • Company C4 Therapeutics, Inc.
  • Price $5.31
  • Changes Percentage (-0.56%)
  • Change -$0.03
  • Day Low $5.21
  • Day High $5.48
  • Year High $11.88

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 10/30/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $12.50
  • High Stock Price Target $20.00
  • Low Stock Price Target $9.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.37
  • Trailing P/E Ratio -1.97
  • Forward P/E Ratio -1.97
  • P/E Growth -1.97
  • Net Income $-132,493,000

Income Statement

Quarterly

Annual

Latest News of CCCC

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.